Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)
|
January 10, 2018
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies
Jacob P van Vloten, Samuel T Workenhe, Sarah K Wootton, et al.
Endocrine-Related Cancer
|
September 16, 2017
Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission
Robert C Mould, Jacob P van Vloten, Amanda W K AuYeung, et al.
Cells
|
September 23, 2022
The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy
Jessica A Minott, Jacob P van Vloten, Lily Chan, et al.
Molecular Therapy. Methods & Clinical Development
|
August 8, 2019
Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies
Jacob P van Vloten, Elaine M Klafuric, Khalil Karimi, et al.
The Journal of General Virology
|
December 1, 2016
Truncation of the enzootic nasal tumor virus envelope protein cytoplasmic tail increases Env-mediated fusion and infectivity
Scott R Walsh, Jondavid G de Jong, Jacob P van Vloten, et al.
Molecular Therapy. Methods & Clinical Development
|
February 22, 2019
Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies
Jacob P van Vloten, Lisa A Santry, Thomas M McAusland, et al.
Viruses
|
February 23, 2019
Myeloid Cells during Viral Infections and Inflammation
Ashley A Stegelmeier, Jacob P van Vloten, Robert C Mould, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Kathy Matuszewska, Lisa A Santry, Jacob P van Vloten, et al.
Molecular Therapy. Methods & Clinical Development
|
November 17, 2021
Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy
Jacob P van Vloten, Jessica A Minott, Thomas M McAusland, et al.
Scientific Reports
|
July 28, 2021
Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis
Amanda W K AuYeung, Robert C Mould, Ashley A Stegelmeier, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
Journal of Immunology (Baltimore, Md. : 1950)
|
January 10, 2018
Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies
Jacob P van Vloten, Samuel T Workenhe, Sarah K Wootton, et al.
Endocrine-Related Cancer
|
September 16, 2017
Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission
Robert C Mould, Jacob P van Vloten, Amanda W K AuYeung, et al.
Cells
|
September 23, 2022
The Role of Neutrophils in Oncolytic Orf Virus-Mediated Cancer Immunotherapy
Jessica A Minott, Jacob P van Vloten, Lily Chan, et al.
Molecular Therapy. Methods & Clinical Development
|
August 8, 2019
Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies
Jacob P van Vloten, Elaine M Klafuric, Khalil Karimi, et al.
The Journal of General Virology
|
December 1, 2016
Truncation of the enzootic nasal tumor virus envelope protein cytoplasmic tail increases Env-mediated fusion and infectivity
Scott R Walsh, Jondavid G de Jong, Jacob P van Vloten, et al.
Molecular Therapy. Methods & Clinical Development
|
February 22, 2019
Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies
Jacob P van Vloten, Lisa A Santry, Thomas M McAusland, et al.
Viruses
|
February 23, 2019
Myeloid Cells during Viral Infections and Inflammation
Ashley A Stegelmeier, Jacob P van Vloten, Robert C Mould, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 13, 2018
Combining Vascular Normalization with an Oncolytic Virus Enhances Immunotherapy in a Preclinical Model of Advanced-Stage Ovarian Cancer
Kathy Matuszewska, Lisa A Santry, Jacob P van Vloten, et al.
Molecular Therapy. Methods & Clinical Development
|
November 17, 2021
Production and purification of high-titer OrfV for preclinical studies in vaccinology and cancer therapy
Jacob P van Vloten, Jessica A Minott, Thomas M McAusland, et al.
Scientific Reports
|
July 28, 2021
Mechanisms that allow vaccination against an oncolytic vesicular stomatitis virus-encoded transgene to enhance safety without abrogating oncolysis
Amanda W K AuYeung, Robert C Mould, Ashley A Stegelmeier, et al.
Page
of 3